<DOC>
	<DOCNO>NCT00402532</DOCNO>
	<brief_summary>The purpose study determine whether Everolimus effective treatment prevention chronic graft dysfunction chronic graft rejection lung transplantation .</brief_summary>
	<brief_title>Immunosuppressive Therapy With Certican ( Everolimus ) After Lung Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<criteria>Recipient Single Bilateral Lung Transplantation Informed consent Recipients able receive Everolimus week 3 Lung Transplantation woman childbearing potential must negative pregnancy test within 48 hour enrolment woman childbearing potential must use appropriate contraceptive method enrolment , study 8 week end study donor must relevant pulmonary disease donor must oxygen partial pressure high 300 mmHg FiO 1.0 positive endexpiratory pressure 5 cm H2O . systemic infection donor donor : sign symptom aspiration donor : severe pulmonary injury contusion donor : malignant neoplasm lung donor : HIV positive recipient receive immunosuppressive agent use protocol recipient participate within 30 day study start currently participate another investigational drug trial HIV positive recipient systemic infection recipient recipient combined/ multiple transplantation pregnancy recipient recipient signs/ Symptoms impair wound heal pulmonary anastomosis recipient still artificial respiration able swallow tablet week 3 transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Lung Transplantation</keyword>
	<keyword>Immunosuppression</keyword>
	<keyword>Mortality</keyword>
	<keyword>Graft rejection</keyword>
	<keyword>Bronchiolitis obliterans</keyword>
	<keyword>Opportunistic infection</keyword>
	<keyword>Nephrotoxicity</keyword>
</DOC>